wherein:

R_1 and R_2 are independently selected from the group consisting of H, R, and ArR-, or R_1 and R_2 are joined to form a ring;

R_3 and R_4 are independently selected from the group consisting of H, R, and ArR-, or R_3 and R_4 are joined to form a ring;

R_5 is selected from the group consisting of H, R, ArR-, and Ar;

R_6 is selected from the group consisting of H, R, and ArR-;

R_7 and R_8 are independently selected from the group consisting of: H, R, and ArR-; and

R_9 is:  ;

R is a saturated or unsaturated moiety having a linear, branched, or non-aromatic cyclic skeleton containing one to ten carbon atoms, zero to four nitrogen atoms, zero to four oxygen atoms, and zero to four sulfur atoms, and the carbon atoms are optionally substituted with: =O, =S, -OH, $-OR_{10}$, $-O_2CR_{10}$, -SH, $-SR_{10}$, $-SOCR_{10}$, $-NH_2$, $-NHR_{10}$, $-N(R_{10})_2$, $-NHCOR_{10}$, $-NR_{10}COR_{10}$, -I, Br, -C1, -F, -CN, $-CO_2H$, $-CO_2R_{10}$, -CHO, $-COR_{10}$, $-CONH_2$, $-CONHR_{10}$, $-CON(R_{10})_2$, -COSH,

$-COSR_{10}$, $-NO_2$, $-SO_3H$, $-SOR_{10}$, $-SO_2R_{10}$, wherein R_{10} is a linear, branched or cyclic, one to ten carbon atom saturated or unsaturated alkyl group;

the ring formed by joining R_1 and R_2 or by joining R_3 and R_4 is a three to seven member non-aromatic cyclic skeleton within the definition of R,

C1 Conclude

X is a moiety selected from the group consisting of -OH, -OR, =O, =S, $-O_2CR$, -SH, -SR, -SOCR, $-NH_2$, -NHR, $-N(R)_2$, -NHCOR, -NRCOR, -I, -Br, -Cl, -F, -CN, $-CO_2H$, $-CO_2R$, -CHO, -COR, $-CONH_2$, -CONHR, $-CON(R)_2$, -COSH, -COSR, $-NO_2$, $-SO_3H$, -SOR, and $-SO_2R$;

Ar is an aromatic ring selected from the group consisting of phenyl, naphthyl, anthracyl, phenanthryl, furyl, pyrrolyl, thiophenyl, benzofuryl, benzothiophenyl, quinolinyl, isoquinolyl, imidazolyl, thiazolyl, oxazolyl, and pyridinyl, optionally substituted with R or X;

Y is a linear, unsaturated, two to six carbon atom alkyl group, optionally substituted with R, ArR-, or X, provided however if R8 is H, then the optional substituents on Y are limited to R and ArR- wherein R is linear, branched or cyclic alkyl of one to ten carbon atoms and Ar is phenyl, napthyl, anthracyl, or phenanthryl; and,

Z is a moiety selected from the group consisting of: -OH, -OR; -SH; -SR; $-NH_2$; $-NHCH(R_{11})COOH$; and $-NRCH(R_{11})COOH$, wherein R_{11} is a moiety having the formula: R, or $-(CH_2)_nNR_{12}R_{13}$, wherein n=1-4 and R_{12} and R_{13} are independently selected from the group consisting of H; R; and -C(NH) (NH_2)

or pharmaceutically acceptable salt thereof.

68. (Once Amended) The compound of claim 22, having the configuration:



70. (Once Amended) The compound of claim 22, having the configuration:



73. (Once Amended) A pharmaceutical composition suitable for treating tumors comprising an anti-tumor effective amount of at least one compound of claim 22 and acceptable pharmaceutical excipient.

74. (Once Amended) A method of treating tumors by arresting cell mitosis in a patient in need of such treatment comprising administering to said patient an anti-mitotic effective amount of at least one compound of claim 22.

REMARKS

Claims 22-74 are pending in the present application. Claim 74 has been withdrawn from consideration by the Examiner. Claims 22, 68, 70, 73, and 74 have been amended in